NASDAQ
55.29USD
+0.00 (+0.01%)
We have scored 24 news catalysts on The Cooper Companies, Inc. (COO) over the past 12 months. The biggest single-day move next to one of them came Dec 5, 2025, when COO closed +5.7%: “Dow Jones Today: Stocks Tick Higher After Key Inflation Data; Netflix To Buy Warner Bros. in $83B Deal”. Coverage across the window leans positive (average ticker sentiment +0.38). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.8B
P/E
—
EPS
—
Beta
0.82
52W range
51.01-89.83
Day range
54.56–55.55
Open
55.13
Prev close
55.29
Volume
1.3M
Avg volume
3.1M
Dividend
0.00
IPO
1983-01-21
Analysts publish price targets on COO, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
12 analyst price targets from $59 to $86
as of 2026-09-14
The market is 21% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about The Cooper Companies, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for COO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
The price sits at the very bottom of the published model range ($59 to $86), 21% below the median target, meaning the market has explicitly rejected the bullish consensus and is pricing in a severe growth shortfall.
What the disagreement turns on
The central question is whether the CooperVision revenue drag is a temporary inventory correction or a permanent loss of market share to silicone hydrogel products, and unit volume data can directly test this.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
